Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 66

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 66
---
 insurance costs, consulting and legal services, along with facility and maintenance costs attributable to general and administrative
functions.

Financial Expenses

Financial expenses consist primarily of the
impact of exchange rates derived from re-measurement of monetary balance sheet items denominated in non-dollar currencies. Other financial
expenses include bank fees and interest on stockholders’ loans.

<div align='center'>37

Results of Operations</div>

Following the closing on July 23, 2024 of the
Share Exchange Agreement with LipoVation whereby LipoVation because a wholly owned subsidiary of Revium Rx, in accordance with ASC 810,
Lipovation’s financial data below are presented as the “Predecessor” for periods prior to the closing of the acquisition.
Revium Rx, which includes consolidation of Lipovation subsequent to the acquisition, is the “Successor” for periods after
the closing of the Business Combination.

As a result of the application of the acquisition
method of accounting in the Successor period, the financial data for the Successor period are presented on a full step-up basis as a
result of the acquisition and are therefore not comparable to the financial statements of the Predecessor period that are not presented
on the same full step-up basis.

Overview

Successor for the six months period ended June 30, 2025, the Predecessor for the six months period ended June 30, 2024

The following tables present selected financial
data for the Successor for the six months period ended June 30, 2025 and the Predecessor for the six months period ended June 30,
2024.

|                                     |     |  Successor |       |   |     | Predecessor |       |
|                                     |     |    For the 
 six months 
      ended 
   June 30, |       |   |     |     For the 
  six months 
       ended 
    June 30, |       |
|                                     |     |       2025 |       |   |     |        2024 |       |
| Operating expenses                  |     |            |       |   |     |             |       |
| Research and development expenses   |     |            |   609 |   |     |             | 1,146 |
| General and administrative expenses |     |            | 1,066 |   |     |             |   253 |
| Operating loss                      |     |            | 1,675 |   |     |             |